Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour

Christoph Oing; Pasquale Rescigno; Pia Paffenholz; Julia Heinzelbecker; Anna Patrikidou; Richard S Matulewicz; Robert Huddart

doi:10.1016/j.euf.2024.06.011

Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour

Eur Urol Focus. 2024 May;10(3):361-363. doi: 10.1016/j.euf.2024.06.011. Epub 2024 Aug 1.

Authors

Christoph Oing¹, Pasquale Rescigno², Pia Paffenholz³, Julia Heinzelbecker⁴, Anna Patrikidou⁵, Richard S Matulewicz⁶, Robert Huddart⁷

Affiliations

¹ Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK; Northern Centre for Cancer Care, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: [email protected].
² Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK; Northern Centre for Cancer Care, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
³ Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Centre for Integrated Oncology Köln-Bonn, Cologne, Germany.
⁴ Department of Urology and Pediatric Urology, University Medical Centre Saarland and Saarland University, Homburg/Saar, Germany.
⁵ Genitourinary Oncology Group, Departments of Cancer Medicine and Early Drug Development, Gustave Roussy, Villejuif, France.
⁶ Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Institute of Cancer Research and Royal Marsden Hospital, London, UK.

PMID: 39095218
DOI: 10.1016/j.euf.2024.06.011

Abstract

Treatment de-escalation strategies in patients with seminoma with retroperitoneal metastases are being investigated in ongoing clinical trials. Primary retroperitoneal lymph node dissection conducted by expert surgeons may avoid any cytotoxic treatment and related long-term side effects in ≥70% of patients with clinical stage IIA/B seminoma.

MeSH terms

Humans
Lymph Node Excision* / methods
Lymphatic Metastasis
Male
Neoplasm Staging*
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / secondary
Neoplasms, Germ Cell and Embryonal / surgery
Retroperitoneal Neoplasms / pathology
Retroperitoneal Neoplasms / secondary
Retroperitoneal Neoplasms / surgery
Retroperitoneal Space
Seminoma* / pathology
Seminoma* / surgery
Testicular Neoplasms* / pathology
Testicular Neoplasms* / surgery